| Company | Type Of | Number Of | Amount | Investors; Placement Agents; |
| (Symbol) | Financing | Shares, Units | Raised (M) | Details (Date) |
| Or Warrants (M) | ||||
| Alpha-Beta Tech- | Private | ND | $3 | The company agreed to sell $3M in convertible |
| nology Inc. (ABTI) | placement | preferred stock to a single institutional investor; | ||
| the investor bought $1.5M immediately and | ||||
| will purchase the rest on the effectiveness of | ||||
| a resale registration statement (10/22) | ||||
| Creative | Sale of OP-1 | — | $20 | Creative BioMolecules sold its OP-1 manufacturing |
| BioMolecules Inc. | manufacturing | rights and facilities to development partner | ||
| (CBMI) | rights and | Stryker Corp.; Creative gets increased royalties | ||
| facilities | on sale of the product for orthopedic and dental | |||
| reconstruction in place of manufacturing profits | ||||
| per terms of the partners' original agreement (10/16) | ||||
| Cytogen Corp. | Equity line | — | $12 | Cytogen secured a $12M common stock equity line |
| (CYTO) | from Kingsbridge Capital, an institutional investor | |||
| based in Ireland; the company can draw up to $12M | ||||
| in cash over 2 years in exchange for common stock | ||||
| (at a 15% discount to market); Cytogen must register | ||||
| the shares before it can draw down the cash (10/26) | ||||
| Medarex Inc. | Payment of | — | $15.5 | Medarex received a $15M principal payment and |
| (MEDX) | principal and | $0.5M in interest from Cell Genesys Inc. The | ||
| interest on note | payment is in satisfaction of a note issued in con- | |||
| nection with a cross-license and settlement agree- | ||||
| ment from 3/97 between Medarex subsidiary | ||||
| GenPharm International Inc. and Cell Genesys (10/1) | ||||
| RiboGene Inc. | Equipment | — | $2 | Finova Capital Corp. will provide RiboGene |
| (RBO) | financing | with $2M in financing in the form of secured | ||
| equipment loans over the next 12 months (10/7) | ||||
| TOTAL: $52.5M | ||||
| NOTES: | ||||
| ND = Not disclosed, reported and/or available; S = Shares; U = Units; W = Warrants | ||||
| The financings in this chart include loans, bridge financings and other interim measures as well as sales of business units, debt offerings, rights offerings, exercises of warrants, institutional offerings of registered stock and standard private placements. | ||||
To read more on related topics, click on one of the words below.